TAO Synergies Inc. (TAOX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
TAO Synergies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| YA Yinka Akinsola Blue Trust Inc. | 2,832 | $18,549.6 | $10,818.24 | -$7,731.36 | -41.68% |
| LWM Lodestone Wealth Management LLC Lodestone Wealth Management LLC | 20 | $74 | $76.4 | $2.4 | 3.24% |
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 500 | $1,314 | $1,910 | $596 | 45.36% |
TAO Synergies Inc. (TAOX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has TAO Synergies Inc. ever had a stock split?
TAO Synergies Inc. Profile
| Biotechnology Industry | Healthcare Sector | Joshua N. Silverman CEO | NASDAQ (CM) Exchange | 87167T300 CUSIP |
| US Country | 4 Employees | - Last Dividend | 5 Apr 2024 Last Split | 8 Dec 2020 IPO Date |
Overview
Synaptogenix, Inc. is a biopharmaceutical company engaged in the development of innovative therapies for neurodegenerative diseases, with a primary focus on Alzheimer's disease. Incorporated in 2012 and based in New York, New York, Synaptogenix is dedicated to advancing its product candidates through pre-clinical and clinical development stages. The company's research and development efforts are centered on a drug candidate known as Bryostatin-1, which shows promise for not only Alzheimer's disease but potentially for a range of other cognitive diseases and dysfunctions.
Products and Services
- Bryostatin-1 for Alzheimer's Disease
Synaptogenix's flagship product, Bryostatin-1, is under development as a treatment for Alzheimer's disease. This drug candidate is based on extensive research and is currently in various stages of clinical development. Bryostatin-1 has been shown to have potential in restoring synaptic density and function, which are often diminished in Alzheimer's patients.
- Bryostatin-1 for Other Neurodegenerative or Cognitive Diseases and Dysfunctions
Beyond Alzheimer's disease, Synaptogenix is exploring the therapeutic applications of Bryostatin-1 for a variety of other neurodegenerative or cognitive disorders. This includes fragile X syndrome, multiple sclerosis, and Niemann-Pick type C disease. The versatility of Bryostatin-1 demonstrates Synaptogenix's commitment to addressing the broader spectrum of cognitive diseases and dysfunctions, potentially offering hope to patients with conditions that currently have limited treatment options.
